Celldex Therapeutics

Scratching the surface of the urticaria pipeline
Scratching the surface of the urticaria pipeline
EP Vantage
chronic urticaria
Sanofi
Dupixent
Regeneron
Novartis
Roche
Xolair
Allakos
AstraZeneca
Celldex Therapeutics
Flag link:
Chronic hives: Four major clinical trials to watch in 2023
Chronic hives: Four major clinical trials to watch in 2023
Clinical Trials Arena
chronic hives
chronic urticaria
clinical trials
Sanofi
Regeneron
dupilumab
Amgen
tezepelumab
Allakos
lirentelimab
Celldex Therapeutics
barzolvolimab
Flag link:
Celldex pins its hopes for a comeback on skin disease drug
Celldex pins its hopes for a comeback on skin disease drug
BioPharma Dive
Celldex Therapeutics
chronic urticaria
Flag link:
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
The Week Ahead In Biotech: ASCO Presentations In The Spotlight
Yahoo/Benzinga
ASCO 2018
European Society of Cardiology
TherapeuticsMD
Abiomed
Incyte
Bluebird Bio
Celgene
Syndax
Loxo Oncology
Exelixis
Karyopharm
Endocyte
Celldex Therapeutics
Jounce Therapeutics
Bristol-Myers Squibb
Nektar
Flag link:
Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff
Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff
Endpoints
Celldex Therapeutics
layoffs
Flag link:
Celldex's highly anticipated breast cancer drug fails to hit the mark in a midstage trial
Celldex's highly anticipated breast cancer drug fails to hit the mark in a midstage trial
Motley Fool
Celldex Therapeutics
triple negative breast cancer
glemba
Flag link:
7 of the Most Shocking Biotech Pipeline Blowups of 2016
7 of the Most Shocking Biotech Pipeline Blowups of 2016
Motley Fool
biotech
Alnylam
revusiran
Clovis Oncology
rociletinib
Celldex Therapeutics
Rintega
Eli Lilly
solanezumab
Novavax
RSV-F
Arrowhead
ARC-520
ARC-521
ARC-AAT
Biomarin
drisapersen
Flag link:
Celldex Cancer Drug Shows Good Early Data
Celldex Cancer Drug Shows Good Early Data
Investopedia
Celldex Therapeutics
CDX-1140
lymphoma
Flag link:
Celldex Acquires Cancer Medicine Company for $62.5 Million
Celldex Acquires Cancer Medicine Company for $62.5 Million
Yahoo
Celldex Therapeutics
M&A
Kolton Pharmaceuticals
Flag link:
These 3 Little Biotechs Just Scored Big
These 3 Little Biotechs Just Scored Big
Motley Fool
biotech
Celldex Therapeutics
melanoma
glemba
Exelixis
Cabometyx
renal cell carcinoma
Tesaro
ovarian cancer
niraparib
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
Exelixis
cabozantinib
Cobimetinib
Celldex Therapeutics
CDX-011
Cerulean Pharma
CRLX101
Medivation
Xtandi
Palatin
bermelanotide
Rexahn
RX-3117
Anthera Pharmaceuticals
Flag link:
Key FDA Decisions and Trial Results Expected in October
Key FDA Decisions and Trial Results Expected in October
24/7 Wall St
FDA
clinical trials
cabozantinib
Cobimetinib
Exelixis
Medivation
Xtandi
Celldex Therapeutics
glemba
Palatin
bremelanotide
CRLX101
Cerulean Pharma
Anthera Pharmaceuticals
Flag link:
3 Shocking Biotech Flops of 2016 So Far
3 Shocking Biotech Flops of 2016 So Far
Motley Fool
biotech
Rintega
Celldex Therapeutics
glioblastoma
Clovis Oncology
rociletinib
lung cancer
NewLink Genetics
algenpantucel-L
pancreatic cancer
Flag link:
4 Cancer Drug Developers You Need to Have on Your Radar This Year
4 Cancer Drug Developers You Need to Have on Your Radar This Year
Motley Fool
cancer
Exelixis
Celldex Therapeutics
Ziopharm
Jazz Pharmaceuticals
Flag link:
Biotech's Top 5 Stock Winners, And Losers, In Q1 2016
Biotech's Top 5 Stock Winners, And Losers, In Q1 2016
Forbes
biotech
PTC Therapeutics
Celldex Therapeutics
Biocryst
Puma Biotechnology
Portola Pharmaceuticals
MedicNova
BioTie Therapies
Editas Medicine
AveXis
Inovio
Flag link:
Celldex Brain Tumor Vaccine Fails Pivotal Clinical Trial
Celldex Brain Tumor Vaccine Fails Pivotal Clinical Trial
TheStreet.com
Celldex Therapeutics
clinical trials
Rintega
glioblastoma multiforme
Flag link:
3 Biotech Stocks With Jaw-Dropping Growth Potential in 2016
3 Biotech Stocks With Jaw-Dropping Growth Potential in 2016
Motley Fool
biotech
Inovio
Celldex Therapeutics
Novavax
Flag link:
10 Worst NASDAQ Biotech Stocks in the Third Quarter
10 Worst NASDAQ Biotech Stocks in the Third Quarter
TheStreet.com
Orexigen
Immunomedics
Celldex Therapeutics
Arena Pharmaceuticals
Theravance
Karyopharm
Raptor Pharmaceutical
Verastem
Tetraphase
Xoma
Flag link:
3 Experimental Cancer Drugs Investors Should Be Closely Watching
3 Experimental Cancer Drugs Investors Should Be Closely Watching
Motley Fool
cancer
JCAR015
Juno Therapeutics
Celgene
Celldex Therapeutics
Rentiga
Geron
imetelstat
Flag link:
ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate
ASCO Wrapup: Immunotherapy Shines, Hope For Brain Tumors, & The Great Cancer Drug Price Debate
Forbes
ASCO
cancer immunotherapy
glioblastoma multiforme
Merck
Genentech
Celldex Therapeutics
Flag link:

Pages